The FDA granted Fast Track designation to TRI-611 for ALK-positive non-small cell lung cancer, signaling regulatory interest in the program as an additional option after resistance to existing ALK tyrosine kinase inhibitors. TRI-611 is positioned as an oral, brain-penetrant “molecular glue degrader” intended to drive degradation of ALK fusion proteins via cereblon-mediated ubiquitination. The designation targets patients who have already received two or more ALK TKIs, a group where central nervous system metastases and serial resistance remain recurring clinical challenges. Fast Track does not equal approval, but it can enable more frequent FDA interactions and potential rolling review later. Biotech developers watching ALK space will likely focus on how quickly TRI-611 can generate safety and efficacy signals in early trials—given the ongoing need for mechanisms distinct from active-site inhibition.